Area of research
Physiology · Neurology
Research interest
Research interests include Alzheimer's disease research and treatments, Neuroinflammation and Neurodegeneration Mechanisms, S100 Proteins and Annexins, and Neuroscience and Neuropharmacology Research.
Retraction notice to "An apoE-derived mimic peptide, COG1410, alleviates early brain injury via reducing apoptosis and neuroinflammation in a mouse model of subarachnoid hemorrhage" [Neurosci. Lett. 627 (2016) 92-99].
Elevated tumor NOS2/COX2 promotes immunosuppressive phenotypes associated with poor survival in ER- breast cancer.
ApoE COG 133 mimetic peptide improves survival, infection burden, and <i>Clostridioides difficile</i> toxin-A-induced intestinal damage in mice.
Pros and Cons of APOE4 Homozygosity and Effects on Neuroplasticity, Malnutrition, and Infections in Early Life Adversity, Alzheimer's Disease, and Alzheimer's Prevention.
Apolipoprotein E4 and Alzheimer's disease causality under adverse environments and potential intervention by senolytic nutrients.
ApoE Mimetic Peptides to Improve the Vicious Cycle of Malnutrition and Enteric Infections by Targeting the Intestinal and Blood-Brain Barriers.
Apolipoprotein E mimetic peptide COG1410 combats pandrug-resistant Acinetobacter baumannii
Caspase-1 and the inflammasome promote polycystic kidney disease progression.
Apolipoprotein E mimetic peptide COG1410 combats pandrug-resistant <i>Acinetobacter baumannii</i>.
PPP2CA Is a Novel Therapeutic Target in Neuroblastoma Cells That Can Be Activated by the SET Inhibitor OP449.
Metabolism-Based Gene Differences in Neurons Expressing Hyperphosphorylated AT8- Positive (AT8+) Tau in Alzheimer's Disease.
Translational animal models for Alzheimer's disease: An Alzheimer's Association Business Consortium Think Tank
Translational animal models for Alzheimer's disease: An Alzheimer's Association Business Consortium Think Tank.
Synergic effect of OP449 and FTY720 on oral squamous cell carcinoma.
The N-terminal Set-β Protein Isoform Induces Neuronal Death
Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia